Soft Tissues Sarcoma is the rare and diverse group of cancers that develop from tissues such as blood vessels, muscles, fats, nerves, and deep skin tissues etc. There are around 50 different types of soft tissue sarcoma that are identified, the common types of soft tissue sarcoma include liposarcomas, leiomyosarcomas, and others. The soft tissue sarcoma can be treated by the combined chemotherapy, radiotherapy, and surgery to remove the tumor. If a surgical procedure is not required, chemotherapy can be used alone.
Treatment demand continues to grow for soft tissue sarcoma. The increased prevalence rate remains the major driver of the global soft tissue sarcoma market. Market Research Future (MRFR) reports that the global soft tissue sarcoma market is set to grow at 8.2% CAGR during the assessment period (2017-2023).
The R&D pipelines are expected to grow in the forthcoming years. In addition, increased focus on pacing up approval process is likely to expand overall care and treatment quality for soft tissue sarcoma in the years to come. Sunitinib (sutent), doxorubicin (adriamycin), trabectedin (yondelis), bevacizumab (avastin), and sirolimus (rapamune) are some of the pertinent drugs that are currently available. Nevertheless, adverse side-effects of the treatment, high cost and approval delays are some of the major market impediments.
Global Soft Tissue Sarcoma Market: Regional Segmentation
The regions covered in the report include the Middle East & Africa (MEA), Asia Pacific (APAC), Europe and the Americas. In terms of revenue, the global soft tissue sarcoma market is dominated by the Americas with North America being the brighter market. This is mainly owing to the presence of an advanced healthcare system in the region. Moreover, the rise in prevalence rate has also allowed the market to climb faster in the region. The data released by American Cancer Society, in 2016, approximately 12,390 people were suffering from soft tissue sarcoma or related cancer.
The market is also witnessing a steady growth in Europe. Higher rate of incidence and favourable reimbursement policies are some of factors that can be linked with the market growth in the region.
Get customized Sample with complete Toc, Inclusive of COVID-19 Industry Analysis:https://www.marketresearchfuture.com/sample_request/5304
Asia Pacific (APAC) accounts for the third spot in the global soft tissue sarcoma market in terms of revenue. It is projected that the APAC soft tissue sarcoma market will witness a strong growth over the next couple of years. Healthcare policy reforms and increased efforts to improve healthcare services in countries such as China, India, Taiwan among others.
Global Soft Tissue Sarcoma Market: Segmental Overview
The segmental analysis of the market has been conducted on the basis of disease type, treatment, end-users and distribution channel. Based on disease type, the market has been segmented into regional sarcoma, metastatic sarcoma, and local sarcoma.
On the basis of treatment type, the market has been segmented into radiation therapy, anti-angiogenesis drugs, targeted therapy, and chemotherapy. The radiation therapy segment is further sub-segmented into external radiation therapy and internal radiation therapy
Global Soft Tissue Sarcoma Market: Competitive Landscape
GlaxoSmithKline plc (U.K), Pfizer, Inc. (U.S.), F. Hoffmann-La Roche AG (Genentech) (Switzerland), Celgene Corporation (U.S.), Eli Lilly and Company (U.S.), Johnson & Johnson Services, Inc. (U.S.), Bristol-Myers Squibb (U.S.), and Teva Pharmaceutical Industries Ltd (Israel) are among key company discussed in the MRFR’s report.
Have Any Query? Connect with Our Research Expert 24*7:https://www.marketresearchfuture.com/enquiry/5304
- Reportedly, the American pharmaceutical giant Eli Lilly has purchased the global rights for “CNTX-0290” the non-opioid pain candidate from Centrexion Therapeutics. The deal could garner close to $1 billion, plus royalties for the Boston-based company. CNTX-0290 is development phase and will be used for chronic pain associated with neuropathic, inflammatory and mixed pain conditions
- Epizyme, Inc, a late-stage biopharmaceutical firm focusing on new epigenetics therapies has recently released new data on on tazemetostat from the epithelioid sarcoma cohort of its active Phase 2 research in patients with molecularly defined solid tumours.
Market Research Future
Phone: +1 646 845 9312
NOTE: Our team of researchers are studying Covid-19 and its impact on various industry verticals and wherever required we will be considering covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.